223 related articles for article (PubMed ID: 29752752)
21. Phase III Study to Assess Long-Term (52-Week) Safety and Efficacy of Mirabegron, a β
Yamaguchi O; Ikeda Y; Ohkawa S
Low Urin Tract Symptoms; 2017 Jan; 9(1):38-45. PubMed ID: 28120446
[TBL] [Abstract][Full Text] [Related]
22. Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial.
Staskin D; Frankel J; Varano S; Kennelly M; Newman DK; Rosenberg MT; Shortino DD; Jankowich RA; Mudd PN
Int J Clin Pract; 2022; 2022():6475014. PubMed ID: 35685566
[TBL] [Abstract][Full Text] [Related]
23. Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: a case report.
Kato T; Mizuno K; Nishio H; Yasui T; Hayashi Y
J Med Case Rep; 2021 Feb; 15(1):86. PubMed ID: 33602290
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.
Di Salvo J; Nagabukuro H; Wickham LA; Abbadie C; DeMartino JA; Fitzmaurice A; Gichuru L; Kulick A; Donnelly MJ; Jochnowitz N; Hurley AL; Pereira A; Sanfiz A; Veronin G; Villa K; Woods J; Zamlynny B; Zycband E; Salituro GM; Frenkl T; Weber AE; Edmondson SD; Struthers M
J Pharmacol Exp Ther; 2017 Feb; 360(2):346-355. PubMed ID: 27965369
[TBL] [Abstract][Full Text] [Related]
25. A Randomized, Double-Blind, Placebo-Controlled, Bridging Study to Evaluate the Efficacy and Safety of Vibegron in Treating Korean Patients With Overactive Bladder.
Shin JH; Jeong SJ; Kim SO; Oh CY; Chung KJ; Shin DG; Kim TH; Kwon J; Shin JH; Bae WJ; Lee KS; Choo MS
Int Neurourol J; 2023 Jun; 27(2):106-115. PubMed ID: 37401021
[TBL] [Abstract][Full Text] [Related]
26. Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial.
Wada N; Mizunaga M; Abe N; Miyauchi K; Kobayashi S; Ohtani M; Tsunekawa R; Nagabuchi M; Morishita S; Ohyama T; Yamaguchi S; Iuchi H; Noda T; Saga Y; Motoya T; Kawakami N; Nishihara M; Numata A; Kakizaki H
World J Urol; 2024 Mar; 42(1):113. PubMed ID: 38431689
[TBL] [Abstract][Full Text] [Related]
27. Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis.
Chastek B; Carrera A; Landis C; Snyder D; Abedinzadeh L; Bancroft T; Nesheim J; Kennelly M; Staskin D
Adv Ther; 2024 May; 41(5):2086-2097. PubMed ID: 38520502
[TBL] [Abstract][Full Text] [Related]
28. Vibegron for the treatment of overactive bladder: a comprehensive update.
Gleicher S; Sebesta EM; Reynolds WS; Dmochowski R
Expert Opin Pharmacother; 2022 Sep; 23(13):1479-1484. PubMed ID: 36124780
[TBL] [Abstract][Full Text] [Related]
29. Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year.
Chapple CR; Kaplan SA; Mitcheson D; Blauwet MB; Huang M; Siddiqui E; Khullar V
Int J Urol; 2014 Oct; 21(10):960-7. PubMed ID: 25092441
[TBL] [Abstract][Full Text] [Related]
30. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder.
Ohlstein EH; von Keitz A; Michel MC
Eur Urol; 2012 Nov; 62(5):834-40. PubMed ID: 22695239
[TBL] [Abstract][Full Text] [Related]
31. Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meta-analysis.
Jian Z; Yuan C; Li H; Zhang W; Wang K
Int Urol Nephrol; 2020 Dec; 52(12):2215-2221. PubMed ID: 32519241
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Vibegron for the Treatment of Overactive Bladder in Women: A Subgroup Analysis From the Double-Blind, Randomized, Controlled EMPOWUR Trial.
Newman DK; Thomas E; Greene H; Haag-Molkenteller C; Varano S
Urogynecology (Phila); 2023 Jan; 29(1):48-57. PubMed ID: 36384907
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of Vibegron for the treatment of residual overactive bladder symptoms after laser vaporization of the prostate: A single-center prospective randomized controlled trial (VAPOR TRIAL).
Seki N; Masaoka H; Song Y; Dejima T; Sato Y; Maeda S
Low Urin Tract Symptoms; 2024 Jul; 16(4):e12529. PubMed ID: 38956950
[TBL] [Abstract][Full Text] [Related]
34. An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder.
Frankel J; Staskin D; Varano S; Kennelly MJ; Jankowich RA; Haag-Molkenteller C
Ther Clin Risk Manag; 2022; 18():171-182. PubMed ID: 35264853
[TBL] [Abstract][Full Text] [Related]
35. Urodynamic evaluation of the efficacy of vibegron, a new β3-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder.
Kitta T; Chiba H; Kon M; Higuchi M; Kusakabe N; Ouchi M; Togo M; Abe-Takahashi Y; Tsukiyama M; Shinohara N
J Pediatr Urol; 2022 Oct; 18(5):563-569. PubMed ID: 35965225
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of the Selective β3 -Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study.
Yamaguchi O; Marui E; Igawa Y; Takeda M; Nishizawa O; Ikeda Y; Ohkawa S
Low Urin Tract Symptoms; 2015 May; 7(2):84-92. PubMed ID: 26663687
[TBL] [Abstract][Full Text] [Related]
37. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
[TBL] [Abstract][Full Text] [Related]
39. Vibegron improves quality-of-life measures in patients with overactive bladder: Patient-reported outcomes from the EMPOWUR study.
Frankel J; Varano S; Staskin D; Shortino D; Jankowich R; Mudd PN
Int J Clin Pract; 2021 May; 75(5):e13937. PubMed ID: 33332699
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of fesoterodine treatment for overactive bladder symptoms in elderly women with and without hypertension.
Yokoyama O; Yamagami H; Hiro S; Hotta S; Yoshida M
Int J Urol; 2018 Mar; 25(3):251-257. PubMed ID: 29224251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
